Interferon beta-1b biosimilar - Pfenex

Drug Profile

Interferon beta-1b biosimilar - Pfenex

Alternative Names: PF 530

Latest Information Update: 12 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfenex - Stelis Biopharma (JV)
  • Developer Pfenex
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 09 May 2016 Pfenex plans a pivotal pharmacokinetics and pharmacodynamics study and a immunogenicity trial for Multiple Sclerosis
  • 14 Apr 2015 Phase-I clinical trials in Multiple sclerosis (In volunteers) in Australia (SC)
  • 16 Mar 2015 Pfenex terminates its agreement with Stelis Biopharma for Multiple sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top